[HTML][HTML] Immunogenic cell death: an emerging target in gastrointestinal cancers
Immunogenic cell death (ICD) is a regulated form of cell death that induces the activation of
both innate and adaptive immune responses through the release of damage-associated …
both innate and adaptive immune responses through the release of damage-associated …
[HTML][HTML] Downstream targets of VHL/HIF-α signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance
Simple Summary Clear cell renal cell carcinoma (ccRCC) progression, which is the most
common form of kidney cancer, is associated with the loss of the Von Hippel-Lindau (VHL) …
common form of kidney cancer, is associated with the loss of the Von Hippel-Lindau (VHL) …
Overall survival with adjuvant pembrolizumab in renal-cell carcinoma
TK Choueiri, P Tomczak, SH Park… - … England Journal of …, 2024 - Mass Medical Soc
Background Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE …
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE …
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Background Effective adjuvant therapy for patients with resected localised renal cell
carcinoma represents an unmet need, with surveillance being the standard of care. We …
carcinoma represents an unmet need, with surveillance being the standard of care. We …
The 2022 updated european association of urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma
Abstract In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly
improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) …
improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) …
[HTML][HTML] High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints
AM Raghubar, NA Matigian, J Crawford… - npj Precision …, 2023 - nature.com
Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell
renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient …
renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient …
[HTML][HTML] Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario
Standard treatment for localized non-metastatic renal cell carcinoma (RCC) is radical or
partial nephrectomy. However, after radical surgery, patients with stage II-III have a …
partial nephrectomy. However, after radical surgery, patients with stage II-III have a …
All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and …
ABSTRACT Background Immune checkpoint inhibitors (ICIs) have been associated with
acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been …
acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been …
[HTML][HTML] Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic
I Lyskjær, L Iisager, CT Axelsen, TK Nielsen… - Clinical Cancer …, 2024 - AACR
The incidence of renal cell carcinoma (RCC) is increasing worldwide, yet research within
this field is lagging behind other cancers. Despite increased detection of early disease as a …
this field is lagging behind other cancers. Despite increased detection of early disease as a …
[HTML][HTML] Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
T Yanagisawa, T Kawada, F Quhal, K Bekku… - World Journal of …, 2023 - Springer
Purpose To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone
or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) …
or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) …